Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
patent: 5081138 (1992-01-01), Gillard et al.
patent: 2004/0198800 (2004-10-01), Allan et al.
patent: 1749829 (2006-03-01), None
Miller et al., “Identification and isolation of a membrane protein necessary for leukotrine production,” Nature 343:278-281 (1990) Abstract only.
PCT/US06/39421 Search Report dated Jan. 18, 2008.
Evans Jillian F.
Hutchinson John H.
Prasit Petpiboon Peppi
Stock Nicholas Simon
Amira Pharmaceuticals, Inc.
Seaman Margaret D.
Wilson Sonsini Goodrich & Rosati
5-lipoxygenase-activating protein (FLAP) inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with 5-lipoxygenase-activating protein (FLAP) inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-lipoxygenase-activating protein (FLAP) inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2749768